Chimerix (CMRX) Begins Phase 2/3 Study of DSTAT in Acute Lung Injury for Patients with Severe COVID-19

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Chimerix (CMRX) Begins Phase 2/3 Study of DSTAT in Acute Lung Injury for Patients with Severe COVID-19

Chimerix Announces Initiation of a Phase 2/3 Study of DSTAT in Acute Lung Injury for Patients with Severe COVID-19

April 29, 2020 7:00 AM EDT

FDA Clearance to Proceed with Phase 2/3 Randomized, Double-Blind, Placebo Controlled Study

Mechanisms of Action May Address Overactive Inflammatory Response, Including Underlying Causes of Blood Coagulation Disorders Associated with COVID-19

Company to Host Conference Call Today at 8:30 a.m. ET

DURHAM, N.C., April 29, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced the Companys initiation of a Phase 2/3 study of dociparstat sodium (DSTAT) in COVID-19 patients with acute lung injury... More